extensively drug-resistant tuberculosis

Myanmar: I have defeated TB and I wish the same for other patients

by

Multi-drug resistant tuberculosis is one of the most complex types of tuberculosis you can get. As opposed to drug-sensitive, which responds well to the medication, multi-drug resistant tuberculosis, by its very name, is resistant to some of the drugs used to treat the disease. This makes the response more complicated, often requiring the doctors to … Read more

MSF: TB test price reduction by Cepheid and Danaher is an important step in the right direction

by

Cepheid and its parent company Danaher announced today that they are reducing the price of the Xpert MTB/RIF test for TB by 20 percent in high-TB-burden countries from US$9.98 to $7.97 per test.  This reduction is a significant step, considering the corporations have refused to reduce the price of this test for over ten years. While … Read more

Ahead of UN TB High-Level Meeting, US corporations J&J and Cepheid must pledge access to lifesaving TB medicines and tests for everyone in need

by

TB is curable but remains the world’s leading infectious disease killer 12 September 2023, Geneva/New York – Next week, world leaders meet for the second-ever global tuberculosis (TB) High-Level Meeting at the United Nations (UN) in New York, to endorse ambitious commitments to ramp up TB testing, treatment and prevention in light of innovative medical … Read more

MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics

by

MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics. Recent deal offering controlled generics access in limited countries does not go far enough.   Delhi/Cape Town/Geneva, 18 July, 2023 – As Johnson & Johnson’s (J&J) 20-year … Read more

MSF applauds Indian Patent Office’s rejection of Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug

by

Mumbai, 23 March 2023 – Today, the 2019 patent challenge by two tuberculosis (TB) survivors, Nandita Venkatesan and Phumeza Tisile, was successful: the Indian Patent Office rejected the US pharmaceutical corporation Johnson & Johnson’s (J&J) attempt to extend its monopoly in India on the TB drug bedaquiline beyond the primary patent’s expiry this July. Médecins … Read more

Tuberculosis: Promising new tuberculosis drug pretomanid approved, but will it be affordable?

by

GENEVA/NEW YORK – Doctors Without Borders/Médecins Sans Frontières (MSF) welcomes the approval by the US Food and Drug Administration (FDA) of a combination regimen containing a new drug, pretomanid, for the treatment of extensively drug-resistant tuberculosis (XDR-TB). As the third new drug developed for TB in over half a century, and the first to be … Read more